Forskning
Udskriv Udskriv
Switch language
Bispebjerg Hospital - en del af Københavns Universitetshospital
Udgivet

The Prevalence of Subtypes of Type 2 Inflammation in an Unselected Population of Patients with Severe Asthma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Systematic Assessment of Difficult-to-Treat Asthma: Principles and Perspectives

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Desloratadine Use During Pregnancy and Risk of Adverse Fetal Outcomes: A Nationwide Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy

    Publikation: Bidrag til tidsskriftReviewpeer review

  4. Development of the International Severe Asthma Registry (ISAR): a modified Delphi study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Reply to Crépeaux et al and Blasco

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

Vis graf over relationer

BACKGROUND: With the introduction of different targeted therapies for type 2 (T2)-high asthma, there is an urgent need for markers to guide the choice of treatment. T2-high asthma includes different clinical phenotypes of asthma, but the prevalence and impact of activation of different T2 inflammatory pathways is unknown.

OBJECTIVE: To describe the level of coexpression of clinically available T2 inflammatory markers in patients with severe asthma, and the relationship with clinical characteristics and comorbidities.

METHODS: Patients with severe asthma according to European Respiratory Society/American Thoracic Society guidelines were examined prospectively including sputum induction and grouped according to T2 biomarkers: blood eosinophilia (≥0.3 × 109/L), total IgE (≥150 U/mL), and fractional exhaled nitric oxide (≥25 parts per billion).

RESULTS: We found 116 (70%) of the 166 patients to have at least 1 T2 biomarker elevated: 39% had 2 or more elevated biomarkers, whereas 31% had only 1 biomarker elevated. Concomitant airway and systemic eosinophilia was present in 28% of all patients, corresponding to half (53%) of the patients with either. Expression patterns of the T2 biomarkers were associated with differences in allergic sensitization and the coexistence of nasal polyposis.

CONCLUSIONS: Most patients with severe asthma showed at least 1 T2 inflammatory trait. Coexpression of T2 biomarkers was highly heterogeneous, and different expression patterns were associated with distinct clinical characteristics.

OriginalsprogEngelsk
TidsskriftThe journal of allergy and clinical immunology. In practice
Vol/bind9
Udgave nummer3
Sider (fra-til)1267-1275
Antal sider9
ISSN2213-2198
DOI
StatusUdgivet - mar. 2021

Bibliografisk note

Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

ID: 61434060